Product Review

Product Update: Natera’s Panorama NIPT; Solosec from Symbiomix Therapeutics

OBG Manag. 2017 November;29(11):54
PDF Download

 

NIPT SCREENING FOR TWIN ZYGOSITY AND GENETIC RISK FACTORS

The Natera® Panorama® non-invasive prenatal test (NIPT) now screens twin pregnancies for zygosity and chromosomal abnormalities. Natera says that Panorama is the first NIPT that can determine whether twins are monozygotic (identical) or dizygotic (non-identical/fraternal) as early as 9 weeks’ gestation.

Building on its history as the only NIPT that can differentiate between the mother’s and the baby’s DNA, Panorama is now also the only NIPT to distinguish between each twin’s DNA, says Natera. Panorama’s unique technology enables it to determine zygosity and each twin’s gender while also allowing it to identify risk for more genetic conditions in twin pregnancies than other NIPTs, including monosomy X, sex chromosome trisomies, and 22q11.2 deletion syndrome.

FOR MORE INFORMATION, VISIT: http://www.panoramatest.com/panorama-test/

NEW DRUG FOR TREATING BACTERIAL VAGINOSIS

Solosec™ (secnidazole), a 5-nitroimidazole antibiotic, has been given FDA approval for treatment of bacterial vaginosis (BV) in adult women, according to manufacturer Symbiomix Therapeutics. The drug, consisting of oral granules, can be given as a single 2-g dose, and taken with or without a meal. Symbiomix Therapeutics says that Solosec is clinically proven to normalize BV symptoms of odor and discharge.

Symbiomix Therapeutics reported that FDA approval was supported by comprehensive studies that found the single-dose secnidazole 2g was efficacious. All treatment-emergent adverse effects were mild or moderate in intensity; no serious adverse events were reported. Solosec will be available to patients in the first quarter of 2018.

FOR MORE INFORMATION, VISIT: https://symbiomix.com/sym-1219/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

Next Article:

MACRA Monday: Screening for hypertension